PEREGRINE PHARMACEUTICALS, INC. (NASDAQ:PPHM) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On March 13, 2017, Peregrine Pharmaceuticals, Inc. (the Company)
issued a press release to report the Companys financial results
for the third quarter ended January 31, 2017. A copy of the press
release is attached to this Current Report on Form 8-K as Exhibit
99.1. No additional information is included in this Current
Report on Form 8-K.
The information included in this Current Report on Form 8-K,
including the exhibit hereto, shall not be deemed filed for
purposes of, nor shall it be deemed incorporated by reference in,
any filing under the Securities Act of 1933 or the Securities
Exchange Act of 1934, except as expressly set forth by specific
reference in such a filing.
ITEM 7.01REGULATION FD DISCLOSURE
On March 13, 2017, at 4:30 p.m. EDT/1:30 p.m. PDT, the Company
will host a conference call to discuss its third quarter ended
January 31, 2017 financial results. The webcast of the conference
call will be archived on the Companys website for approximately
30 days.
ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS
(d)Exhibits. The following material is filed as an exhibit to
this Current Report on Form 8-K:
Exhibit
Number
99.1Press Release issued March 13, 2017
About PEREGRINE PHARMACEUTICALS, INC. (NASDAQ:PPHM)
Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company’s subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing. PEREGRINE PHARMACEUTICALS, INC. (NASDAQ:PPHM) Recent Trading Information
PEREGRINE PHARMACEUTICALS, INC. (NASDAQ:PPHM) closed its last trading session up +0.112 at 0.763 with 3,341,541 shares trading hands.
